

**MISSISSIPPI DIVISION OF MEDICAID**  
**Pharmacy & Therapeutics Committee**  
**Woolfolk Building**  
**Conference Center East, Room 145**  
**Jackson, MS 39201-1399**  
**August 8, 2017**  
**10:00am to 5:00pm**

**AGENDA**

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Division of Medicaid Update
- V. Approval of May 9, 2017 Meeting Minutes
- VI. PDL Compliance/Generic Percent Report Updates
- VII. Drug Class Announcements
- VIII. Public Comment
- IX. New Therapeutic Class Review
  - a. Rosacea Treatments
  - b. Movement Disorder Agents
- X. New Drug/New Generic Reviews
  - a. Arymo ER (Analgesics, Narcotic – Long Acting)
  - b. Morphabond (Analgesics, Narcotic – Long Acting)
  - c. Alunbrig (Antineoplastics –Selected Systemic Enzyme Inhibitors)
  - d. Rydapt (Antineoplastics –Selected Systemic Enzyme Inhibitors)
  - e. Zejula (Antineoplastics –Selected Systemic Enzyme Inhibitors)
  - f. Xadago (Antiparkinson’s Agents – MAOI)
  - g. Kisqali (Aromatase Inhibitors)
  - h. Dupixent (Atopic Dermatitis)
  - i. Utibron (Brochodilators & COPD Agents – Combinations)
  - j. AirDuo (Glucocorticoids (Inhaled) –Combinations)
  - k. Xultophy (Hypoglycemics, Incretin Mimetics/Enhancers)
  - l. Synjardy XR (Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors- Combinations)
  - m. Trulance (Irritable Bowel Syndrome/Short Bowel Syndrome Agents/Selected GI Agents)
  - n. Xermelo (Irritable Bowel Syndrome/Short Bowel Syndrome Agents/Selected GI Agents)
  - o. Ocrevus (Multiple Sclerosis Agents)
  - p. Emflaza (Muscular Dystrophy Agents)
- XI. Other Business
- XII. Next Meeting Dates
  - a. Thursday, November 2, 2017
  - b. Tuesday, February 13, 2018
- XIII. Adjournment